BioNTech Investor Day Presentation Deck

Oncology pipeline: Significant progress and expansion in 2022 Drug class Platform mRNA Cell therapies Antibodies Fix Vac iNeST RiboMabs RiboCytokines CAR T cells + CARVac Neoantigen-based T cells TCR engineered T cells Next-gen checkpoint immunomodulators Product candidate Indication (targets) Adjuvant pancreatic ductal adenocarcinoma ¹ Intratum oral immunotherapy SAR441000 (BNT131)³ Solid tumors (IL-12sc, IL 15-sushi, GM-CSF, IFNa) BNT141 Multiple solid tumors (CLDN 18.2) BNT142 BNT 151 BNT152, BNT153 BNT211 BNT212 BNT221 (NEO-PTC-01) To be selected Multiple solid tumors (CD3×CLDN6) Multiple solid tumors (optimized IL-2) Multiple solid tumors (IL-7, IL-2) Multiple solid tumors (CLDN6) Pancreatic, other cancers (CLDN18.2) Multiple solid tumors GEN1046 (BNT311)4 GEN1042 (BNT312)4 BNT321 (MVT-5873) BNT411 Targeted cancer antibodies Toll-like receptor binding BNT111 BNT112 BNT113 BNT 1151 BNT 116 Autogene cevum eran (BNT122)² Advanced and R/R melanoma Prostate cancer HPV16+ head and neck cancer Ovarian cancer NSCLC 1L melanoma Adjuvant colorectal cancer Solid tumors All tumors Metastatic NSCLC (PD-L1x4-1BB) Multiple solid tumors (PD-L1×4-1BB) Multiple solid tumors (CD40×4-1BB) Pancreatic cancer (sLea) Solid tumors (TLR7) SMIM SMIM, small molecule immunomodulators. 1 Investigator-initiated Phase 1 trial; 2 Collaboration with Genentech; 3 Collaboration with Sanofi; 4 Collaboration with Genmab. Pre-clinical Phase 1 Phase 2 Phase 3 IMAJU Milestones FPD June 2021 FPD, July 2021 Start Phase 1/2 Data H2 2022 FPD, Dec 2021 Follow-up trial FPD Jan 2022 Start Phase 1/2 Ph 2 planned 2023 FPD, Dec 2021 BIONTECH 93

View entire presentation